Endovascular treatment of complex abdominal aortic aneurysm disease

Sveinsson, Magnus

2021

Document Version: Publisher's PDF, also known as Version of record

Link to publication

Citation for published version (APA):

Total number of authors: 1

General rights
Unless other specific re-use rights are stated the following general rights apply:
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal

Read more about Creative commons licenses: https://creativecommons.org/licenses/

Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Endovascular treatment of complex abdominal aortic aneurysm disease

MAGNÚS SVEINSSON
CLINICAL SCIENCES | FACULTY OF MEDICINE | LUND UNIVERSITY
MAGNÚS SVEINSSON was born in Reykjavík, Iceland in 1977. He received his medical degree from the University of Iceland in 2006. Moving with his family to Helsingborg Sweden he completed specialization in general surgery in 2013, and subsequently specialized in vascular surgery in 2018 after training at Helsingborg Regional Hospital as well as in Vascular Center Malmö in Sweden where the research projects in this thesis were undertaken.
Endovascular treatment of complex abdominal aortic aneurysm disease

Magnús Sveinsson

DOCTORAL DISSERTATION

by due permission of the Faculty of Medicine, Lund University, Sweden. To be defended at Skåne University Hospital Malmö, 22nd of May 2021 at 09:00.

Faculty opponent

Professor Emeritus Jan Brunkwall.
Dep. of Vascular and Endovascular Surgery, University of Cologne, Germany
Endovascular treatment options for abdominal aortic aneurysm disease have evolved rapidly in the last years. Continuous efforts aim towards securing patient safety and durable stentgrafts. Juxtarenal abdominal aortic aneurysms (jAAA) pose a specific challenge, demanding complex device design and detailed planning, as well as various technical difficulties during fenestrated endovascular aneurysm repair (FEVAR). Adequate proximal seal and durable target vessel patency are of particular concern, driving continuous research and innovation in graft design and methodical advances. Similarly to primary endovascular repair for juxtarenal aneurysm, FEVAR is increasingly used as secondary repair after failed previous aneurysm reconstruction. Variable aneurysm anatomy requires individually tailored grafts in each case, which is a limitation in urgent settings. Stentgrafts with a standardized configuration, available “off-the-shelf”, have been designed to address this issue with promising short-term results. FEVAR is a safe and effective means of managing jAAA with good short-term outcomes, but long-term data is limited.

The specific aim of this thesis was:

1. To evaluate the impact of experience of FEVAR on graft design and clinical outcome in patients with jAAA
2. To evaluate short-term performance and outcome of fenestrated and branched stentgrafts when used as secondary proximal repair after previous infrarenal aortic reconstruction
3. To evaluate the performance and long-term clinical outcome of the COOK Zenith p-Branch device for jAAA in elective and emergent settings
4. To evaluate the long-term outcome of FEVAR in patients with jAAA

FEVAR is an effective and safe treatment option for jAAA disease. Increasing experience results in decreased intra-operative fluoroscopy time and contrast medium load despite more complex stentgraft design. FEVAR as secondary repair after failed previous infrarenal treatment for AAA is safe and effective, but meticulous pre-operative imaging and planning is essential. The COOK Zenith p-Branch device performs well in treatment of jAAA both electively and emergently in selected patient groups, particularly in urgent circumstances. However, a custom made device should be favored in appropriate cases. With increasing experience a reduction is seen in operative mortality, 5-year mortality and over-all aneurysm sac diameter, as well as increased 5-year re-intervention free survival. FEVAR is a safe and effective treatment for jAAA with good outcomes in the short- and long-term, although the need for re-intervention remains high.
Endovascular treatment of complex abdominal aortic aneurysm disease

Magnús Sveinsson
Coverphoto and figure 1 from Shutterstock ©

Figure 2, 3, 5, 6, 7: Permission for use granted by COOK Medical, Bloomington, Indiana.

Copyright pp 1-70 Magnús Sveinsson

Paper 1 © Elsevier Inc.

Paper 2 © Elsevier Inc.

Paper 3 © Elsevier B.V.

Paper 4 © by the Authors (Manuscript unpublished)

Lund University, Faculty of Medicine
Department of Clinical Sciences

ISBN 978-91-8021-054-6
ISSN 1652-8220

Printed in Sweden by Media-Tryck, Lund University
Lund 2021
To my family

“Nothing worth having comes easy”
-Theodore Roosevelt-
# Table of Contents

Abbreviations .................................................................................................................. 8  

Original Papers .................................................................................................................. 9  

Introduction ...................................................................................................................... 11  

**Abdominal aortic aneurysm disease** ............................................................................ 13  
  History .............................................................................................................................. 13  
  Aetiology .......................................................................................................................... 14  
  Epidemiology ................................................................................................................... 15  
  Diagnosis .......................................................................................................................... 16  
  Invasive treatment .......................................................................................................... 17  
    Open surgical repair ...................................................................................................... 17  
    Endovascular aneurysm repair .................................................................................... 18  
  Post-operative imaging surveillance .............................................................................. 19  

**Fenestrated aortic stentgrafts** ....................................................................................... 21  
  History .............................................................................................................................. 21  
  Stentgraft material and design ..................................................................................... 22  
  Sealing zones and endoleak ........................................................................................... 26  

**Aims** ................................................................................................................................ 29  

**Material and methods** .................................................................................................. 31  
  Patients ............................................................................................................................ 31  
  Stentgrafts ...................................................................................................................... 31  
  Imaging and measurements ........................................................................................... 32  
  Statistics .......................................................................................................................... 32  
  Ethical aspects ................................................................................................................ 32  

**Results** .......................................................................................................................... 35  
  Paper I .............................................................................................................................. 35  
  Paper II ............................................................................................................................. 36  
  Paper III ............................................................................................................................ 38
## Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>AAA</td>
<td>Abdominal aortic aneurysm</td>
</tr>
<tr>
<td>BEVAR</td>
<td>Branched endovascular aortic repair</td>
</tr>
<tr>
<td>CBCT</td>
<td>Cone beam computed tomography</td>
</tr>
<tr>
<td>CMD</td>
<td>Custom made device</td>
</tr>
<tr>
<td>CT</td>
<td>Coeliac trunc</td>
</tr>
<tr>
<td>CTA</td>
<td>Computed tomography angiogram</td>
</tr>
<tr>
<td>DSA</td>
<td>Digital subtraction angiography</td>
</tr>
<tr>
<td>DUS</td>
<td>Doppler ultrasound</td>
</tr>
<tr>
<td>EL</td>
<td>Endoleak</td>
</tr>
<tr>
<td>EVAR</td>
<td>Endovascular aortic repair</td>
</tr>
<tr>
<td>ESVS</td>
<td>European Society for Vascular Surgery</td>
</tr>
<tr>
<td>FEVAR</td>
<td>Fenestrated endovascular aortic repair</td>
</tr>
<tr>
<td>FU</td>
<td>Follow-up</td>
</tr>
<tr>
<td>GFR</td>
<td>Glomerular filtration rate</td>
</tr>
<tr>
<td>ICU</td>
<td>Intensive care unit</td>
</tr>
<tr>
<td>IMA</td>
<td>Inferior mesenteric artery</td>
</tr>
<tr>
<td>IV</td>
<td>Intravenous</td>
</tr>
<tr>
<td>jAAA</td>
<td>Juxtarenal abdominal aortic aneurysm</td>
</tr>
<tr>
<td>OSR</td>
<td>Open surgical repair</td>
</tr>
<tr>
<td>OTS</td>
<td>Off-The-Shelf</td>
</tr>
<tr>
<td>rAAA</td>
<td>Ruptured abdominal aortic aneurysm</td>
</tr>
<tr>
<td>SMA</td>
<td>Superior mesenteric artery</td>
</tr>
<tr>
<td>TV</td>
<td>Target vessel</td>
</tr>
</tbody>
</table>
Original Papers

This thesis is based on the following papers, referred to hereafter by their Roman numerals:


Papers are reprinted with permission from respective publishers.
Introduction

The aorta is the largest artery in the human body. It arises from the base of the heart and runs its course longitudinally through the torso, delivering oxygenated blood to the rest of the body and so sustaining life in all body parts and organs. As in all blood vessels, the tubular wall of the aorta is comprised of three layers, the innermost intima, the media, and the enveloping adventitia.

Aneurysm formation has been described in most large arteries of the body. The formation of an aneurysm of the abdominal aorta has wide implications and can develop into a life-threatening situation in the advent of a rupture. When rupture occurs great volumes of blood are lost from the circulation which in many cases is instantly lethal. Great progress has been made in the recent decades regarding diagnosis and treatment as well as understanding the underlying pathology and risk factors involved. An aneurysm can form anywhere along the aorta, but is most commonly localized in the abdominal part of the vessel. Roughly half of abdominal aortic aneurysms form below the arterial branches that supply abdominal organs such as liver, spleen, intestines and kidneys with blood. The other half have more complex anatomy and form close to, or directly involve these visceral branches which calls for more extensive and complicated treatment strategies.

Invasive or surgical treatment of aortic aneurysm disease is primarily aimed at preventing a rupture of the vessel, or the life-saving containment of a bleeding should rupture occur. Different treatment modalities are available, but they share the common purpose of effectively replacing the vessel wall of the affected aortic segment with a prosthetic graft, thus relieving the strain of systolic blood pressure to which all arteries of the body are ceaselessly subjected. These aortic grafts can be produced from a variety of materials but are primarily manufactured from synthetic fabric.

One treatment option is endovascular aortic repair (EVAR). This minimally invasive method involves placing an aortic prosthesis in the site of the aneurysm trough percutaneous access to the arterial system via the groin vessels. The minimally invasive nature of the procedure adds to its attractiveness for both patient and physician. This methodology for treating aortic aneurysms has evolved tremendously in the past decades, and recent studies have showed some favourable outcomes when compared with the more traditional open surgical approach. Furthermore, this principle of treatment has been implemented in the management
of complex aneurysm disease with the addition of fenestrations to the design of the prosthesis, through which blood flow to the abdominal organs is secured. This treatment method is called fenestrated endovascular aortic repair (FEVAR).

The aim of this thesis was to investigate the feasibility of FEVAR in treating abdominal aortic aneurysm disease by scrutinizing device design and patient outcomes after treatment.
Abdominal aortic aneurysm disease

History

Due to the outstanding preservation techniques practiced in Egypt 3500 years ago studies have revealed that arterial calcification was not uncommon in the region, and even earlier papyrus writings suggest the identification of aortic aneurysm formation by contemporary physicians\(^1\). Records describe surgical treatment for aortic aneurysms in Greece as early as the 2\(^{\text{nd}}\) century AD, with ligatures applied to the arteries entering and leaving the aneurysm and subsequent evacuation of the aneurysm contents but leaving the sac in place\(^2, 3\).

The formation of an aneurysm (the dilation of an artery) was a known affliction through the centuries to come but reasonable attempts to find a cure or effective treatment did not emerge until the middle of the 20\(^{\text{th}}\) century. The term aortic aneurysm was introduced to western medicine by Paré and Vesalius in the mid sixteenth century\(^4\). Some 200 years later physicians began to give serious thought to definitive treatment options to prevent rupture of aortic aneurysms. The earliest attempts were concentrated on exclusion of the aneurysm from active circulation. The combination of both proximal and distal ligation of the aneurysm proved most successful but inevitably rendered patients vulnerable for severe ischemia in the lower extremities\(^5\). Some attempts to induce coagulation inside the aneurysm were made, often by introducing metal wire and electrothermic coagulation, with varying success\(^6, 7\). The principal of stimulating perianeurysmal fibrosis with cellophane wrapping of the aorta gained some foothold later on\(^8, 9\). The results were surprisingly good albeit unpredictable.

Direct surgical repair began to evolve after the pivotal work of Matas in 1888 when he described obliterate endoaneurysmorrhaphy, an approach based on conserving arterial lumen with intravascular suturing of arterial openings inside the aneurysmal sac\(^1\). Subsequently he described a reconstructive technique of excising parts of the aneurysm wall and restoring continuity of the vessel with arteriography using the remaining arterial tissue\(^10, 11\). His efforts paved the way for Carrel and Guthrie\(^3\) who shortly thereafter began experimenting with aortic repair using homografts and vascular anastomoses. With further advancements in homograft preservation methods the stage was set for modern open surgical aortic repair.
The first successful repair of an abdominal aortic aneurysm with human homograft replacement was performed by Dubost in 1951\textsuperscript{12}. After this pivotal case, numerous reports of operations with successful outcome saw the light of day in the following years\textsuperscript{13-16}. In the wake of these events the hunt for suitable synthetic materials to replace homografts as a base for aortic reconstruction led to the development of the elasticized woven Dacron graft still used in open surgical aortic repair (OSR) to this day.

The minimally invasive approach to managing aortic aneurysm disease emerged with the introduction of Endovascular Aortic Aneurysm Repair (EVAR) described by Parodi in 1991\textsuperscript{17}. He demonstrated how blood flow through the aorta can be maintained while excluding the aneurysm by using a Dacron tube with a metal scaffolding introduced using cannulation of the common femoral artery. Ironically the discovery had already been made by Volodos in 1986\textsuperscript{18}, but never reached the community of western medicine due to geographical and linguistic barriers. In the three decades that have passed since EVAR has gained a decisive worldwide foothold in the management of aortic aneurysms with steadily growing experience in device design, patient selection and operative techniques\textsuperscript{19-21}.

### Aetiology

An abdominal aortic aneurysm (AAA) is defined as a focal and persistent dilation of the vessel beyond 150\% of the diameter of an adjacent healthy vessel segment\textsuperscript{22}, or more practically a >30 mm dilation of the artery\textsuperscript{23, 24}. Direct external and environmental factors such as arterial inflammatory disease, connective tissue disorders and trauma account for a small portion of AAAs, while the remaining majority constitute degenerative AAAs\textsuperscript{25}. The degenerative formation of an AAA is a complex multifactorial process of which the exact mechanism is not well understood, but it is generally accepted that inflammation and matrix degeneration in the media combine in a resulting weakening of the vessel wall which ultimately leads to dilation\textsuperscript{26, 27}. Degradation of elastin and collagen as well as apoptosis of smooth muscle cells in the media, driven by the release of proteolytic enzymes such as metalloproteinase from white blood cells, affects the structural integrity of the vessel wall rendering it unfit to combat the strain of systemic blood pressure\textsuperscript{25, 28}. Studies have shown significantly greater metalloprotease activity in the distal parts of the aorta compared to more proximally, partly explaining why AAA is five times more likely than thoracic aneurysms\textsuperscript{29}.

All parts of the aorta are subject to aneurysm formation. Formation below the diaphragm is collectively called abdominal aortic aneurysm. An AAA located exclusively below the renal arteries is referred to as infrarenal, while AAAs close to or involving the level of the renal arteries are known as juxtarenal and pararenal.
respectively. Suprarenal AAA refers to aneurysm formation that proximally exceeds the level of the splanchnic arteries\textsuperscript{30}.

True aortic aneurysms can vary in morphology, generally divided into fusiform (95\%) and saccular aneurysms (5\%)\textsuperscript{31}. A widely accepted hypothesis states that saccular aneurysms have a different aetiology, related to localized infection, atherosclerotic plaque instability or trauma, and are more prone to rupture\textsuperscript{32}. Evidence for this is however not undisputed\textsuperscript{33}.

Epidemiology

Figures on the prevalence of AAA rely heavily on studies predominantly including men due to higher incidence among members of the male gender. The incidence of AAA has been decreasing in the last 30 years owing to less smoking and healthier lifestyle. Prevalence differs in geographical regions of the world, probably due to differences in exposure to risk factors\textsuperscript{34}. According to recent studies the prevalence in Sweden is 1.5-2.6\% in men at the age of 65\textsuperscript{35, 36}.

A number of independent risk factors for the development of AAA have been identified. The most common risk factors are history of smoking, age, male gender, family history, hypertension, hyperlipidaemia, obesity and chronic obstructive pulmonary disease (COPD)\textsuperscript{34, 37, 38} while protective factors include black race, Diabetes Mellitus and regular exercise\textsuperscript{39}. Recent studies have shown that smoking or a history of smoking increases the risk of aneurysm formations as high as elevenfold\textsuperscript{35, 37}, and men are six times more likely to develop AAA compared to women\textsuperscript{35, 40}.

Studies have shown a mean annual aneurysmal growth rate of 1.2 – 3.6 mm/year, and the growth rate seems to increase exponentially as the aneurysm diameter increases\textsuperscript{26, 37}.

It is estimated that mortality rate for patients with ruptured AAA (rAAA) is 65-85\%\textsuperscript{41-43}, and about 4-600 persons die due to rAAA in Sweden each year\textsuperscript{35, 36}. The risk of rupture is associated with maximum AAA diameter. Estimations indicate a yearly risk of approximately 1\%, 3\%, 4\% and 6\% in AAAs of 40-54 mm, 55-60 mm, 60-70 mm and respectively\textsuperscript{44-46}, although the estimated risk of rupture for AAA \(\geq 70\) mm has been reported to be as high as 30\%\textsuperscript{47}. Mortality associated with rAAA in developed countries has been declining in recent years due to healthier living standards, technical advances, better pre- and post-operative management and the introduction of screening\textsuperscript{48}. Although the overall incidence of AAA is lower among females, studies have shown up to fourfold rupture rate in women\textsuperscript{49, 50} highlighting the need for further focus on gender differences in the natural history of AAA.
Diagnosis

The majority of AAA are asymptomatic and accidentally diagnosed. Symptoms of AAA include pulsating abdominal mass and/or abdominal, back or flank discomfort or pain\textsuperscript{25, 51}. These symptoms may be due to aneurysmal pressure on adjacent retroperitoneal structures, inflammation, rapid AAA growth or rupture. Additionally, an AAA may cause indirect symptoms such as embolic events in the lower extremities, heart failure due to aortocaval fistula or lower extremity oedema due to compression of the inferior vena cava\textsuperscript{28}. However, the clinical diagnosis of AAA is often hard with physical examination alone since symptomatic aneurysms are uncommon. It is estimated that 66-75\% of AAA are asymptomatic\textsuperscript{52}.

Ultrasonography is a safe and readily accessible method for initial assessment and follow-up surveillance of AAA, as well as for screening purposes\textsuperscript{25}, and is generally the method of choice in these regards. With reported 95-100\% sensitivity and close to 100\% specificity, DUS is an excellent tool for initial evaluation of AAA size in anteroposterior, transverse and longitudinal dimensions\textsuperscript{43-55}. The imaging modality has certain limitations. Results of DUS are equipment- and operator-dependent, and factors such as abdominal girth and bowel gas hamper diagnostic capacity in up to 2\% of cases\textsuperscript{56, 57}.

As aneurysm diameter progresses to the level of treatment indication, CTA is usually the preferred imaging modality to more closely assess the size and anatomy of the aneurysm as a part of pre-operative planning\textsuperscript{58-61}. CTA has also been shown to be highly effective in the diagnosis of rAAA\textsuperscript{62}. This imaging method requires the administration of IV contrast medium to enhance the lumen of the vessel, and offers an excellent platform for mapping and measurement of aneurysm morphology. Images can further be reconstructed in dedicated three-dimensional computer software to produce a longitudinal centre-line through the entire aorta, providing valuable aid for the surgeon in the choice of optimal treatment strategy\textsuperscript{63, 64}.

Early detection of AAA through screening programmes is an effective way of reducing mortality\textsuperscript{65}. An AAA-screening programme was launched in 2006 in Sweden, reaching nation-wide coverage in 2015\textsuperscript{56}. A similar programme was implemented in the UK in 2009\textsuperscript{66}, and various AAA-screening programs exist in the United States as well\textsuperscript{67, 68}. An early diagnosis of AAA greatly improves the possibility of prophylactic treatment and thereby reducing the incidence of often fatal aneurysm rupture\textsuperscript{67, 69}. In Sweden all men are invited to a single DUS scan at the age of 65. Attendance between 2006 and 2014 was 84\% and it is estimated that 90 premature deaths are avoided yearly\textsuperscript{36}. 
Invasive treatment

As the aneurysm diameter increases, a threshold is eventually reached when the risk of aneurysm rupture surpasses the risks involved with invasive treatment. Earlier, aortic reconstruction was considered feasible at a cut-off point of 5 cm AAA diameter. In the wake of the UKSAT trial\(^7\) and the ADAM trial\(^\text{15}\), both concluding no benefit of intervention over surveillance of small AAAs, a more standardized conformity among physicians began to take shape\(^7\text{1-73}\). Current guidelines recommend invasive management of asymptomatic fusiform AAA at a maximal diameter of >55 mm for men and >50 mm for women\(^4\text{0, 74}\). Two main methods of invasive treatment AAA are practiced to varying degrees depending on local traditions and available resources; open surgical repair and endovascular aneurysm repair.

Open surgical repair

In OSR a large abdominal incision is performed under general anaesthesis to access the abdominal cavity and the retroperitoneal space. After cross-clamping the aorta superiorly and inferiorly to the aortic aneurysm, a graft is sutured in place of the aneurysm to provide a stable and durable artificial substitution for the diseased portion of the vessel and thus alleviating the risk of rupture (figure 1). This procedure is among the most trying interventions in medical practice for the individual to be treated, with reported peri-operative mortality 2.7-5.7\%\(^\text{75, 76}\), and is highly resource consuming in terms of hospital care and long patient convalescence. The risk of peri-operative morbidity and mortality is elevated in the case of

Figure 1. Open Surgical repair.
A woven Dacron graft is sutured end-to-end, replacing the AAA.
juxtarenal- and pararenal AAA surgery, where the level of cross-clamping may temporarily result in restricted blood-flow to viscera and kidneys during surgery. Visceral and renal arteries may in some cases need reimplantation for complete aneurysm repair with a risk of renal function impairment and bowel ischemia.

**Endovascular aneurysm repair**

EVAR is a minimally invasive method of managing AAA and has increasingly been implemented around the world in the last three decades. With the Seldinger-technique access is gained to the arterial system bilaterally through the CFA. A multi-modular endovascular graft system is then introduced and deployed transluminally at the site of AAA using fluoroscopic guidance with DSA, thus reinforcing the vessel wall (figure 2). Great care must be taken to ensure adequate adhesion of the graft system to a healthy aortic segment both proximally and distally to the AAA to secure total exclusion of the aneurysm from pressurized blood-flow. Standard-EVAR requires >15 mm healthy aortic segment below the level of the renal arteries to achieve an adequate proximal seal.

![Figure 2. EVAR.](image)

*Figures of the infra-renal main component (A), iliac leg extensions (B) and the complete EVAR system after deployment (C).*

Aneurysm neck-anatomy (distance from lowest renal artery to aneurysm sac) plays a significant role in the invasive management of AAA disease. Neck length of <10 mm, neck angulation of >60°, conical shape and high degree of calcification or thrombus is considered unfavourable, although the requirements of different devices vary. These factors increase the complexity of the aneurysm, and thus the
choice of treatment strategy. Studies on AAA neck suitability for infrarenal endovascular repair differ, with reports of 40-65%\textsuperscript{80-84} depending on patient gender and choice of device.

The endovascular management of complex AAAs with FEVAR is based on the same principles as EVAR, but requires an endograft modified with fenestrations in the graft fabric to ensure unrestricted blood-flow to visceral and renal arteries, as the level of proximal sealing of the graft involves the take-off of these vessels to varying degrees\textsuperscript{85}. The graft fenestrations are in turn fitted with smaller stentgrafts protruding from the TV into the main aortic component to ensure total aneurysm exclusion and uninterrupted blood-flow to the end organ. Treatment with FEVAR comes with a specific set of challenges in terms of pre-operative planning and technical difficulties during deployment. Studies have reported mid-term re-intervention rates of 6.7-16.4%\textsuperscript{86-90} and 1.5-5.2% mortality\textsuperscript{88, 91-93} after FEVAR for jAAA. Issues regarding TV patency are a particular concern as they constitute a notable share of re-interventions. Studies have reported freedom from TV loss of 89-91%\textsuperscript{88, 94, 95} after 5 years. Impairment of renal function is another concern after treatment of jAAA due to manipulation of the renal arteries. Not only are the kidneys subjected to nephrotoxic contrast medium during endovascular procedures, but the multitude of guidewires and catheters used during FEVAR can inflict physical damage to the vessels resulting in diminished blood-flow. Reported incidence of declining renal function after FEVAR is 17-29% of cases over time\textsuperscript{95-99}.

Post-operative imaging surveillance

CTA has traditionally been the modality of choice in radiologic post-operative surveillance after FEVAR\textsuperscript{100} and remains the gold-standard with good inter-observer reproducibility\textsuperscript{101, 102}. The modality provides detailed images in terms of aneurysm sac diameter and morphology, stentgraft performance and endoleak\textsuperscript{103-105}. Imaging with CTA comes however with drawbacks. It is costly and exposes the patient to ionizing radiation\textsuperscript{106} and nephrotoxic contrast medium\textsuperscript{107}. Estimates indicate that 1.5-2.0% of all cancers developed in the United States may be attributable to radiation from computed tomography scans\textsuperscript{108}. 
Fenestrated aortic stentgrafts

History

Real progress in the successful surgical management of aortic aneurysm disease did not emerge until the 1950s with the introduction of the synthetic vascular graft\textsuperscript{12,109}. OSR remained the standard of care for several decades until the independent simultaneous discoveries of great minds around the world led to the birth of EVAR\textsuperscript{110}. Based on the pivotal work of Charles Dotter performing the first transluminal angioplasty of a femoral artery in 1964\textsuperscript{111}, innovation towards endovascular treatment of aortic lesions began to take shape. After years of preclinical experiments, histological research and durability calculations Volodos and his team performed the first EVAR in a human patient successfully treating a thoracic aneurysm in 1991\textsuperscript{112}, and subsequently implementing the technique to successfully treat an AAA with EVAR in 1993\textsuperscript{113}. Concurrently and independently, the vascular surgeon Parodi had also been experimenting with stentgraft design, and went on to successfully treat a patient with AAA in 1991\textsuperscript{17}. In the wake of these events the technique spread rapidly, and the first EVAR procedure using an aorto-uni-iliacal design was performed by Ivancev et al in Malmö in 1993\textsuperscript{114}. Due to the fact that abdominal aortic aneurysm disease often extends to involve the distal aorta and proximal iliac arteries, and thus rendering straight tubular endografts ineffective for complete aneurysm exclusion, efforts quickly arose to design branched endografts extending to the iliac arteries. This resulted in the first multi-modular aorto-bi-iliac stentgraft, the Zenith endograft from COOK inc (Bloomington, IN, USA)\textsuperscript{110}. In addition to the tendency of distal extension of AAA, aneurysms often extend proximally to involve the infrarenal neck (jAAA) or even include the renal arteries (pararenal AAA). With increasing usage and improved techniques it became apparent that further innovations were needed to preserve perfusion to the aortic branches when managing these complex aneurysms. This gave rise to the implementing of fenestrations in the fabric of stentgrafts. The procedure was first described by Park et al in South Korea\textsuperscript{115} and the first successful FEVAR was performed on a patient with jAAA by Andersson in Australia in 1998\textsuperscript{110}. In Malmö Vascular Center, FEVAR was started in late 2002\textsuperscript{90}, and has with increasing experience become the standard of care for complex AAAs. Moreover, FEVAR has increased significantly worldwide in the past decade, particularly in the wake of the approval of the Zenith\textsuperscript{\textregistered} fenestrated AAA endovascular graft in the European Union.
in 2005 and the United States in 2012. The current ESVS guidelines support FEVAR as the primary choice in elective jAAA repair\textsuperscript{40}.

**Stentgraft material and design**

There are currently two different fenestrated CMDs commercially available, the COOK Zenith\textsuperscript{®} fenestrated device (used in all papers included in this thesis) and the Fenestrated Anaconda™ device (Terumo Aortic, Inchinnan, Scotland, UK). Studies have shown good short- and long-time results after treatment with the Anaconda device\textsuperscript{99, 116-120}, although issues with graft limb thromboses and early type I EL have been reported. For the purposes of this thesis, main focus will be on the COOK Zenith\textsuperscript{®} fenestrated and branched AAA endovascular grafts.

The full Zenith\textsuperscript{®} fenestrated stentgraft system (figure 3) is comprised of three components; the fenestrated main body graft, the bifurcated unibody graft and one iliac leg extension graft. The grafts are made of woven polyester sutured to a scaffolding of self-expandable steel stents ensuring that the device takes a native tubular shape once released from its delivery system inside the AAA. The radial force of the stents ensures a tight seal between the graft and healthy vessel wall as well as the between the overlapping material of the joining components, thus facilitating a total exclusion of the aneurysm. In addition, the top stent is free from graft material and fitted with outwards-facing barbes that effectively latch on to the inside of the vessel wall reducing the risk for device migration after deployment\textsuperscript{121}.

![Figure 3. FEVAR.](image)

Figures of the Zenith fenestrated system. Complete FEVAR after deployment (A), fenestrated main body (B), the bifurcated unibody (C), scallop (D) and fenestration (E).
Fenestrations (holes) or scallops (cut-outs) in the graft fabric are located on the proximal portion of the main body graft, reinforced with nitinol rings and indicated with radio-opaque markers. The precise location of the fenestrations is uniquely tailored to the anatomy of the aneurysm to be treated in each individual case, since they have to fit the exact position of the ostium of the TV to which blood-flow must be preserved. A smaller stentgraft is usually placed in the TV through the fenestration to channel the uninterrupted flow directly to the TV without leakage into the aneurysm sac outside the stentgraft system. A tight seal between the TV stent and the fenestration is accomplished by inflating a balloon in the junction.

![Figure 4. The procedure of FEVAR.](image)

The fenestrated main body folded inside the delivery sheath (A), orientation of the fenestrated graft using digital subtraction angiography (B), placement of introducer sheaths into target vessels (C), fully deployed system with TV stentgrafts in place (D) and post-operative computed tomography reconstruction (E).
When the fenestrated main body has been deployed and all respective TVs stented (figure 4), the system is extended distally with the bifurcated unibody and iliac leg extension to complete the exclusion of the aneurysm. All junctions between the stentgraft system and healthy aortic segments as well as overlaps between system components are finally dilated with a large balloon to ensure a tight fit.

Due to the individually tailored nature of CMDs their designing process and delivery can take up to 6-8 weeks, limiting their use to elective aneurysm repair. In the case of more urgent treatment, such as symptomatic aneurysms, rapidly growing aneurysms or ruptures, OTS devices such as the p-Branch and the t-Branch were developed. These devices are designed with standardized configurations of scallops, fenestrations or branches to accommodate as many anatomic aneurysm variations as possible, and thereby readily available “off-the-shelf” in cases requiring emergent treatment of complex AAAs\textsuperscript{122}.

The p-Branch device from COOK Medical (figure 5A) is based on the Zenith platform and is as of yet not commercially available. It is designed with a scallop for the CT and fenestrations for the SMA and renal arteries\textsuperscript{122,124}. The SMA fenestration serves as the reference point to which the remaining fenestrations are measured and plotted on a grid (figure 5B). The renal fenestrations have preloaded guidewires and a funnel shaped pivoted design, with two nitinol rings interlocked by fabric, allowing for a certain degree of movement to adjust the fenestration to adequately fit the ostium of the TV (figure 6). This device is available in two different configurations, A and B, and has been shown to be anatomically applicable in 50-75% of jAAAs\textsuperscript{125-128}. Early and intermediate results support the safety and feasibility of the p-Branch device\textsuperscript{122,123}.

![Figure 5. The COOK Zenith\textsuperscript{R} p-Branch device and planning grid.](image)

Figures of the p-Branch fenestrated device (A) and the planning grid for measurements of suitability (B).
The Zenith® t-Branch™ OTS device (figure 7) was launched in 2012 and is primarily intended for management of TAAA\textsuperscript{129}. Thus, its sealing zone extends proximally to the distal descending aorta. The device is designed with side-branches for all four TVs of the visceral segment of the vessel and through these the TVs are cannulated and stented to ensure uninterrupted blood-flow to the abdominal viscera and kidneys\textsuperscript{130-132}. The device is designed to ideally leave a 1-2 cm gap between a side-branch and its corresponding TV to facilitate cannulation. Reports indicate that the t-Branch endograft is safe\textsuperscript{129} and applicable in 65-80% of thoracoabdominal aneurysms\textsuperscript{133, 134}. A recent meta-analysis of 7 studies with mean FU of 6-43 months reported a pooled rate of 93% technical success and 6% mortality rate after elective and urgent treatment\textsuperscript{135}.

Similarly to the Zenith Fenestrated device, the p-Branch and the t-Branch devices are extended distally with a bifurcated unibody and iliac leg extension for complete exclusion of the aneurysm.
Sealing zones and endoleak

Successful exclusion of the AAA by the stent graft system is crucial. This is only achieved through absolute adhesion between stent graft and healthy aorta both proximally and distally to the aneurysm itself, as well as between the different components of the completed stent graft system. The instructions of use for Zenith® AAA systems dictate a proximal sealing zone >15 mm between the stent graft and a healthy aortic segment, and distally a minimum of 10 mm in the distal iliac arteries. When all components have been placed in their respective locations with adequate overlap between the conjoined components, a large balloon is inflated in all sealing zones securing that all graft components are tightly conjoined, eliminating all pressurized blood-flow from the weakened aneurysm wall. Failure to do so may result in endoleak (EL) and continued strain on the vessel wall with a risk of rupture. EL is one of the main causes for late rupture after endovascular aneurysm repair, and reports show that 13-28% of re-interventions after FEVAR are EL related.

Table I illustrates the different types of EL. Type 1 EL refers to leak between the graft fabric and vessel wall into the aneurysm sac, where type 1a refers to the proximal sealing zone and type 1b refers to the distal sealing zones in the iliac arteries. Type 2 EL is a retrograde leak from smaller branches in the AAA wall such as the IMA and lumbal arteries. Type 3 EL means leakage between graft components, and type 4 is a leak through the graft fabric, either as a lingering ooze between the woven filaments of the graft material (usually self-limiting) or due to a tear in the fabric. Additionally TV branch EL is described as type 1c if there is leakage into the aneurysm sac from the distal end of the TV stent, and type 3 if there
is a leak through a fenestration due to uncomplete sealing between the main graft component and the TV stent\textsuperscript{30}.

### Table I. Different types of endoleak


<table>
<thead>
<tr>
<th>Endoleak</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Type 1</strong></td>
<td>Flow into the AAA sac due to incomplete sealing. 1a proximal, 1b distal, 1c from TV</td>
</tr>
<tr>
<td><strong>Type 2</strong></td>
<td>Retrograde flow into the AAA sac from lumbar arteries, IMA or accessory renal arteries</td>
</tr>
<tr>
<td><strong>Type 3</strong></td>
<td>Flow into the AAA sac due to incomplete seal between graft system components</td>
</tr>
<tr>
<td><strong>Type 4</strong></td>
<td>Leak through the graft fabric</td>
</tr>
</tbody>
</table>
Aims

In the last decades endovascular means of treating AAA have taken a decisive role, shifting the focus from the more traditional method of OSR with robust evidence of comparable and even favorable outcomes regarding effectiveness and patient safety. About half of AAAs are complex with short or hostile neck anatomy, demanding new means of minimally invasive management. The development of fenestrated stentgrafts is under constant refinement to meet the needs of patients with complex AAA anatomy to provide an effective and sustainable repair with FEVAR, both elective and emergent.

The specific aims of this thesis were:

1. To evaluate the impact of experience of FEVAR on graft design and clinical outcome in patients with jAAA.
2. To evaluate short-term performance and outcome of fenestrated and branched stentgrafts when used as secondary proximal repair after previous infrarenal aortic reconstruction.
3. To evaluate the performance and long-term clinical outcome of the COOK Zenith® p-Branch device for jAAA in elective and emergent settings.
4. To evaluate the long-term outcome of FEVAR in patients with jAAA.
Material and methods

Patients

The majority of patients included in the studies in this thesis were treated in Vascular Center Malmö, with additions from other national and international hospitals in two studies. Paper I was a collaboration between Vascular Center in Malmö and Aortic Centre in Lille. Patients with jAAA deemed unfit or high risk for OSR or standard EVAR due to hostile aneurysm neck anatomy and treated with FEVAR between 2002 and 2011 were included in this retrospective study. Patients with thoraco-abdominal disease or with follow-up <12 months were excluded. Paper II was collaborative work in association with the department of vascular surgery in Akademiska Hospital in Uppsala Sweden. Patients receiving fenestrated or branched endografts as a secondary repair due to failing previous open or endovascular infrarenal repair between 2002 and 2015 were included. Patients with thoraco-abdominal disease were excluded. Paper III prospectively included patients meeting the inclusion criteria for the COOK Zenith® p-Branch device (appendix) treated electively and emergently from July 2012 to September 2015. Paper IV was a retrospective cohort study including patients with available FU data from the late-phase cohort from paper I treated at Vascular Center Malmö between 2007 and 2011.

Stentgrafts

The Zenith® Fenestrated AAA endovascular graft (COOK medical ltd., Perth, Australia) was used in all cases in papers I and IV. The Zenith® Fenestrated device and the Zenith® t-Branch® thoracoabdominal device were used in paper II. Paper III evaluated the Zenith® p-Branch device which was exclusively used in all cases. All beforementioned devices were completed with the Zenith® Universal distal body endovascular graft as well as appropriate Zenith® iliac leg extension stentgrafts, except for selected cases in paper II. All fenestration/scallop stents were covered and balloon-expandable. In the earliest treated patients in paper I, small fenestrations were selectively stented and scallops were left unstented. As the treatment experience grew, all fenestrations were progressively stented and scallops were selectively stented depending on TV anatomy and scallop fit. Technical
success was defined in accordance with the SVS/ICCVS reporting standards in papers I-III, and the SVS reporting standards for complex AAA in paper IV.

Imaging and measurements

Pre-operative imaging consisted of CTA in all studies. The earliest scans performed on patients in paper I were selectively done with catheter directed contrast injection from an arterial groin access. As the technology progressed CTA scans with iv contrast injection from a hypodermic needle became standard. Pre-operative images were reconstructed with a mid-lumen center-line in a dedicated 3D-workstation for measurement purposes (Aquarius iNtuition, TeraRecon®, CA, USA). Infrarenal aneurysm neck anatomy was considered hostile if total length was <10 mm, conical in shape or if angulation between neck and aneurysm was >60°. In all papers, the Siemens Artis Zee fixed imaging system (Siemens Medical Solutions, Erlangen, Germany) was used for patient treatment in Vascular Center Malmö, and the same system was used at dep. of Vascular Surgery at Akademiska hospital in Uppsala in paper II. Treatment of patients in Lille France in paper I was performed with OEC 9900 Elite MD mobile C-arm (GE Healthcare, Buc, France). Imaging FU was with CTA as well as plain abdominal X-ray at 1 month (and 6 months in Lille, France) and 1 year post-operatively in paper I. In papers II and IV FU imaging with CTA and plain X-ray was at 1 month and one year post-operatively, and yearly thereafter. In paper III the same protocol was applied with a clinical evaluation at all intervals, with an additional control at 6 months post-operatively. Images were evaluated at the investigative site and by a centralized core laboratory.

Statistics

Statistical analysis was done in IBM® SPSS® Statistics versions 22-26 (SPSS Inc, Chicago, IL). In paper I one-way analysis of variance was used for continuous data, and for percentage comparisons the χ² test was used. P < 0.5 was considered significant. In papers I-IV continuous data was presented as mean (± standard deviation) or median (range). In papers II-IV survival, re-intervention free survival and TV patency were assessed with Kaplan-Meier analysis.

Ethical aspects

In paper I approval of institutional review board was waived as patients were treated under standard clinical practice. All patients gave informed for the procedure and
FU. Paper II was approved by the Regional Ethics Committees at Lund University (2014/732) and at Uppsala University (2017/027). Informed consent was obtained from all participating patients. Paper III was a physician sponsored study. COOK Medical inc. provided stentgrafts. The study was approved by the Regional Ethics Board at Lund University (2012/52) and all participating patients gave written consent. Paper IV was approved by the Regional Ethics Committee at Lund University (2014/732) and all participating patients gave informed consent.
Results

Paper I

A total of 288 patients were included, 100 in the early phase group and 188 in the late phase group. Patient age and comorbidities were not significantly different in the groups apart from the prevalence of hypertension (59% vs 78%, p < 0.01) and renal insufficiency (26% vs 14%, p = 0.05) as is shown in table II. Median follow up was 11.5 ± 2 and 11.7 ± 2 months in the early and late groups respectively. Mean number of employed scallops/fenestrations increased between the groups from 2.7 ± 0.8 to 3.2 ± 0.7 (p < 0.001), and more TVs were stented (64% vs 77%, p < 0.01). Technical success increased from 92% to 98%. Procedure time was unchanged, but fluoroscopy time and iodine load both decreased by 20% (table III). Less use of contrast media did however not result in better plasma creatine levels at patient discharge. Operative mortality was unchanged between the two groups (2% vs 2.1%, P = NS), and there was no significant difference in AAA related mortality (3% vs 3.2%, p = NS) nor overall mortality (4% vs 7%, p = NS). There was no significant difference in the ratio of decreasing aneurysm diameter at one year (54% vs 62%, p = 0.3), and the frequency of reinterventions and EL was not significantly changed (table IV).

<table>
<thead>
<tr>
<th>Table II. Patient demographics</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Early, %</th>
<th>Late, %</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>91</td>
<td>87</td>
<td>ns</td>
</tr>
<tr>
<td>Age (years)</td>
<td>72 ±7</td>
<td>72 ±7</td>
<td>ns</td>
</tr>
<tr>
<td>AAA diameter (mm)</td>
<td>58.9</td>
<td>59.3</td>
<td>ns</td>
</tr>
<tr>
<td>Smoking</td>
<td>82</td>
<td>79</td>
<td>ns</td>
</tr>
<tr>
<td>Hypertension</td>
<td>59</td>
<td>78</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Diabetes</td>
<td>18</td>
<td>17</td>
<td>ns</td>
</tr>
<tr>
<td>Coronary heart disease</td>
<td>49</td>
<td>47</td>
<td>ns</td>
</tr>
<tr>
<td>COPD</td>
<td>39</td>
<td>37</td>
<td>ns</td>
</tr>
<tr>
<td>Renal failure (GFR &lt;60)</td>
<td>26</td>
<td>14</td>
<td>0.05</td>
</tr>
<tr>
<td>CVI</td>
<td>14</td>
<td>11</td>
<td>ns</td>
</tr>
</tbody>
</table>
Table III. Operative results
NS: not significant. Early and late denote early and late groups.

<table>
<thead>
<tr>
<th></th>
<th>Early</th>
<th>Late</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Procedure time (min)</td>
<td>276</td>
<td>280</td>
<td>ns</td>
</tr>
<tr>
<td>Fluoroscopy time (min)</td>
<td>84</td>
<td>68</td>
<td>0.05</td>
</tr>
<tr>
<td>Contrast volume (ml)</td>
<td>254</td>
<td>184</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>Target vessels</td>
<td>2.7</td>
<td>3.2</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Stented target vessels</td>
<td>64%</td>
<td>77%</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>30-day mortality</td>
<td>2.0%</td>
<td>2.1%</td>
<td>ns</td>
</tr>
</tbody>
</table>

Table IV. Results at 1-year follow-up
AAA: abdominal aortic aneurysm, NS: not significant. Early and late denote early and late groups.

<table>
<thead>
<tr>
<th></th>
<th>Early, %</th>
<th>Late, %</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type I endoleak</td>
<td>1.2</td>
<td>1.0</td>
<td>ns</td>
</tr>
<tr>
<td>TV patency</td>
<td>98</td>
<td>98</td>
<td>ns</td>
</tr>
<tr>
<td>Re-interventions</td>
<td>8</td>
<td>12</td>
<td>ns</td>
</tr>
<tr>
<td>Decreasing AAA diameter</td>
<td>54</td>
<td>61</td>
<td>ns</td>
</tr>
<tr>
<td>AAA-mortality</td>
<td>3.0</td>
<td>3.2</td>
<td>ns</td>
</tr>
<tr>
<td>Overall mortality</td>
<td>4</td>
<td>7</td>
<td>ns</td>
</tr>
</tbody>
</table>

Paper II

43 patients were included, 37 (86%) male and 6 (14%) female. Indications for secondary proximal endovascular repair with F/BEVAR was type Ia EL (58%), proximal AAA or pseudo-aneurysm formation (30%) and migration of a previous EVAR system (12%). EVAR was the most common form of previous repair (75%). A fenestrated repair was used in 34 (79%) cases, a branched repair in 8 (19%) cases and in one case a hybrid graft with a branch for the CT and fenestrations for the SMA and renal arteries. A total number of 146 vessels (mean 3.4) were targeted of which 119 (82%) were stented. Technical success was 93%. Major complications were recorded in 20.9% of cases and minor complications in 16.3% in the first 30 days post-operatively. Mean hospital admission duration was 9 days (table V) and 70% of patients needed no ICU care. Median FU was 33 (range 3-120) months, and mean time from primary repair to secondary intervention was 59 (range 5-180) months. TV patency was 97.3% at one month and 95.2% at one year of FU. 12 (28%) patients needed reintervention during the FU period. Peri-operative and 1 year mortality was 0% and 4.7% respectively (table VI), and only one patient died of AAA related causes during the FU period.
Table V. Operative results  
SD: standard deviation of mean

<table>
<thead>
<tr>
<th></th>
<th>Mean</th>
<th>+/- SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Procedure time (min)</td>
<td>331</td>
<td>151</td>
</tr>
<tr>
<td>Fluoroscopy time (min)</td>
<td>104</td>
<td>36</td>
</tr>
<tr>
<td>Contrast load (g)</td>
<td>34.5</td>
<td>19.6</td>
</tr>
<tr>
<td>Fenestrations</td>
<td>3.4</td>
<td></td>
</tr>
<tr>
<td>Stented target vessels</td>
<td>2.8</td>
<td></td>
</tr>
<tr>
<td>Days in hospital</td>
<td>8.9</td>
<td>10.0</td>
</tr>
</tbody>
</table>

Table VI. Follow-up results  
TV: target vessel, FU: follow-up

<table>
<thead>
<tr>
<th></th>
<th>n</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type I endoleak</td>
<td>3</td>
<td>7</td>
</tr>
<tr>
<td>TV patency</td>
<td>138/146</td>
<td>94.5</td>
</tr>
<tr>
<td>Re-intervention</td>
<td>12</td>
<td>27.9</td>
</tr>
<tr>
<td>30 day mortality</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>1 year mortality</td>
<td>2</td>
<td>4.7</td>
</tr>
<tr>
<td>FU time (mean months)</td>
<td>33</td>
<td></td>
</tr>
</tbody>
</table>

Figure 8. Kaplan-Meier estimates of re-interventions and survival  
Time to first re-intervention in months (A), and all-cause mortality after 5 years (B).
Paper III

25 patients treated electively and emergently with the p-Branch device were included in the study. Two patients were subsequently excluded on anatomical grounds, one patient withdrew from the study and one patient was lost to FU. 23 patients were thus part of the peri-operative analysis and 21 patients completed FU. 12 cases were elective repair and 11 emergent. Table VII shows operative outcomes. Mean time to primary intervention was 67 (range 20-112) days in elective cases and 28 (range 0-122) hours in urgent cases. Device configuration A was employed in 15 (65%) of cases and configuration B in the remaining eight (35%) cases. Technical success was 91%. The most common post-operative adverse events were related to renal function with 3 (14%) patients suffering renal insufficiency during the study period. Two patients suffered a myocardial infarction and one developed transient bowel ischemia. No cases of spinal ischemia occurred. Primary TV patency was 98.8% at 30 days, 96.4% at one year, 95.2% at three years and 94.0% at five years, with assisted primary TV patency and secondary TV patency of 100% at all timepoints. 16 reinterventions were performed on 10 (48%) patients (figure 9a). Emergently treated patients were overrepresented, needing 11 reinterventions in 6 patients. The majority of reinterventions were due to TV instability and instability of the iliac extensions. All-cause mortality was 24% and there was no AAA- or procedure related mortality (figure 9b).

Table VII. Operative outcomes.
ICU: intensive care unit. Data are presented as n (%) or median (range).

<table>
<thead>
<tr>
<th>Type of graft</th>
<th>All patients (n = 23)</th>
<th>Elective patients (n = 12)</th>
<th>Emergent patients (n = 11)</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>15 (65)</td>
<td>8 (67)</td>
<td>7 (64)</td>
</tr>
<tr>
<td>B</td>
<td>8 (35)</td>
<td>4 (33)</td>
<td>4 (36)</td>
</tr>
<tr>
<td>Blood loss (ml)</td>
<td>500 (200 - 1200)</td>
<td>500 (300-1000)</td>
<td>700 (200-1200)</td>
</tr>
<tr>
<td>Transfusion units</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>(0)</td>
</tr>
<tr>
<td>Procedure time (min)</td>
<td>283 (161 - 475)</td>
<td>266 (161-475)</td>
<td>284 (200-418)</td>
</tr>
<tr>
<td>Fluoroscopy time (min)</td>
<td>89 (47 - 170)</td>
<td>81 (47-170)</td>
<td>96 (48-126)</td>
</tr>
<tr>
<td>Contrast media dose (ml)</td>
<td>189 (81 - 332)</td>
<td>148 (81-294)</td>
<td>197 (98-332)</td>
</tr>
<tr>
<td>Technical success</td>
<td>21 (91)</td>
<td>12 (100)</td>
<td>9 (82)</td>
</tr>
<tr>
<td>Endoleak at completion</td>
<td>1a (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
</tr>
<tr>
<td></td>
<td>1b (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
</tr>
<tr>
<td></td>
<td>2 (13)</td>
<td>2 (17)</td>
<td>1 (9)</td>
</tr>
<tr>
<td></td>
<td>3 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Hospital days</td>
<td>8 (4 - 57)</td>
<td>6 (4-30)</td>
<td>14 (6-57)</td>
</tr>
<tr>
<td>ICU days</td>
<td>1 (0 - 22)</td>
<td>1 (0-1)</td>
<td>1 (0-22)</td>
</tr>
</tbody>
</table>
Table VIII. Follow-up outcomes.
AAA: abdominal aortic aneurysm. Data are presented as n (%), mean ± standard deviation or median (range)

<table>
<thead>
<tr>
<th></th>
<th>Patients (n = 21)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean follow-up (months)</td>
<td>45 ± 24.4</td>
</tr>
<tr>
<td>AAA diameter</td>
<td></td>
</tr>
<tr>
<td>Increase &gt;5 mm</td>
<td>1 (5)</td>
</tr>
<tr>
<td>Unchanged</td>
<td>7 (33)</td>
</tr>
<tr>
<td>Decrease &gt;5mm</td>
<td>13 (62)</td>
</tr>
<tr>
<td>Device endoleak</td>
<td></td>
</tr>
<tr>
<td>Type 1a</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Type 1b</td>
<td>1 (5)</td>
</tr>
<tr>
<td>Type 2</td>
<td>6 (29)</td>
</tr>
<tr>
<td>Branch endoleak</td>
<td></td>
</tr>
<tr>
<td>Type 1c</td>
<td>1 (5)</td>
</tr>
<tr>
<td>Type 3</td>
<td>2 (10)</td>
</tr>
<tr>
<td>Branch patency</td>
<td></td>
</tr>
<tr>
<td>Occlusion</td>
<td>2 (10)</td>
</tr>
<tr>
<td>Stenosis</td>
<td>3 (14)</td>
</tr>
<tr>
<td>Device related outcomes</td>
<td></td>
</tr>
<tr>
<td>Migration</td>
<td>1 (5)</td>
</tr>
<tr>
<td>Fracture</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Graft limb occlusion</td>
<td>1 (5)</td>
</tr>
<tr>
<td>Days to reintervention (mean)</td>
<td>469 (0 - 1567)</td>
</tr>
<tr>
<td>Days to death (mean)</td>
<td>436 (35 - 1747)</td>
</tr>
<tr>
<td>All deaths</td>
<td>5 (24)</td>
</tr>
<tr>
<td>AAA related deaths</td>
<td>0 (0)</td>
</tr>
</tbody>
</table>

Figure 9. Kaplan-Meier estimates of re-interventions and survival in 21 patients
Time to first re-intervention in months (A), and all-cause mortality after 5 years (B).
Paper IV

94 patients were included in the study, of which 24% were women and 76% were men. Median FU was 89 (range 0-152) months. 280 fenestrations/scallops were employed of which 205 were stented. Technical success was 89.4%. Primary TV patency was 94% ± 1 % at 1 year, 90% ± 2% at 3 years and 89% ± 2% at 5 years (figure 10), and assisted primary patency was 98.8% at 1 year, 98.4 at 3 years and 97.5 at 5 years. 70 reinterventions were undertaken in 37 (39.4%) patients of which 11 (16%) were prompted by endoleak, 27 (39%) were due to failed TV patency, 12 (17%) graft-limb related and 20 (29%) for other causes (table IX). Re-intervention free survival was 88% ± 3% at 1 year, 70% ± 5% at 3 years and 60% ± 5% at 5 years (figure 11). Over-all survival was 39.4% with 95.7% ± 2.1% at 1 year, 87.1% ± 3.5% at 3 years and 71.0 ± 4.7% at 5 years (figure 12). 5 (5.3) patients died of AAA related causes. Aneurysm diameter was decreased or unchanged in 91% of cases. Mean GFR decreased from 59.2 ± 14.9 ml/min/1.73m² pre-operatively to 50.0 ± 18.6 ml/min/1.73 m² at end of FU, and 5 (5.3%) patients developed dialysis dependency during FU.

Table IX. Re-interventions.
Frequency of re-interventions performed with percentage prompted by findings on routine follow-up. AAA: abdominal aortic aneurysm, rAAA: ruptured abdominal aortic aneurysm, n: number of patients, FU: follow-up.

<table>
<thead>
<tr>
<th></th>
<th>n</th>
<th>Routine FU n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Endoleak</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Type Ia</td>
<td>3</td>
<td>1 (33%)</td>
</tr>
<tr>
<td>Type Ib</td>
<td>3</td>
<td>3 (100%)</td>
</tr>
<tr>
<td>Type Ic</td>
<td>1</td>
<td>1 (100%)</td>
</tr>
<tr>
<td>Type II</td>
<td>3</td>
<td>3 (100%)</td>
</tr>
<tr>
<td>Type III</td>
<td>1</td>
<td>0 (0%)</td>
</tr>
<tr>
<td><strong>Target vessel</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stenosis</td>
<td>21</td>
<td>16 (76%)</td>
</tr>
<tr>
<td>Occlusion</td>
<td>6</td>
<td>2 (30%)</td>
</tr>
<tr>
<td><strong>Limb</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stenosis</td>
<td>7</td>
<td>7 (100%)</td>
</tr>
<tr>
<td>Occlusion</td>
<td>5</td>
<td>2 (40%)</td>
</tr>
<tr>
<td><strong>Other</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Compartment syndrome</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Pseudoaneurysm</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Graft limb extension</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Seroma drainage</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Graft infection</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Guidewire perforation</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Completing renal stent</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Embolus from graft limb</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>rAAA</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Proximal AAA formation</td>
<td>1</td>
<td></td>
</tr>
</tbody>
</table>
Figure 10. Kaplan-Meier estimate of primary target vessel patency during follow-up.
TV: target vessel.

Figure 11. Kaplan-Meier estimate of re-intervention free survival.
Figure 12. Kaplan-Meier estimate of all-cause mortality during follow-up
Discussion

Endovascular management of infrarenal AAA has been shown to be a safe and effective method of repair, with outcomes fully comparable to and in some regards even superior to OSR. The COOK Zenith® Fenestrated abdominal aortic endograft was made commercially available in Europe in 2005, and in 2012 in the United States\textsuperscript{141}. In the following years its use has increased explosively, and FEVAR is now supported as the primary choice for managing jAAA\textsuperscript{40}.

Complex AAAs pose considerable challenges in endovascular repair as the proximal sealing zone involves the visceral segment of the abdominal aorta. Early on in our experience the technically challenging catheterization of TV was a limiting factor resulting in increased operative time, radiation time and contrast media volumes compared to infrarenal EVAR. With increasing experience however, we saw a significant reduction in these factors in spite of trends towards including more TVs. Increasing experience also revealed patency issues with unstented scallops, particularly for the SMA. Initially these were left unstented in the belief that accurate per-operative planning would render the scallop positioned correctly. It gradually became apparent that this was not to be taken for granted and operating surgeons increasingly opted to stent scallops as well to avoid post-operative instability in these TVs due to a shunting effect of the device. Gradually a tendency to replace SMA scallops with large fenestrations evolved without affecting operative outcomes or long-term durability. Interestingly, incorporating a higher number of TVs did not lead to decreased type Ia EL, and TV patency remained unaffected when comparing long-term outcomes between patients treated early and late in our experience, casting some doubt on the value of this trend, although aneurysm sac shrinkage and survival improved.

Redo surgery is required in up to 10% of infrarenal aortic repair due to failing endografts or proximally advancing aneurysm formation\textsuperscript{142}. OSR in these circumstances involves substantial trauma for the patient with high risk of procedure-related morbidity, and mortality rates have been reported to be 17-22%\textsuperscript{142-144}. Similarly to primary repair of jAAA, an endovascular approach in secondary repair with F/BEVAR can be a feasible treatment option\textsuperscript{145}. It does however come with its own set of challenges. In paper II we experienced longer operating times and lower technical success rate compared to primary fenestrated repair with CMDs, as well as increased rates of type Ia EL and re-interventions. A number of factors likely contribute to these outcomes. Advancement of delivery
systems and catheters is hampered due to friction against pre-existing graft material which can cause difficulties in correctly orientating fenestrated grafts. This unwanted effect can be counteracted with a “trough-and-through” brachial-femoral access. TV orifices may be difficult to access due to crossing struts of an original EVAR system adding time-consuming technical challenges. This issue can be met with pre-operative angiography during which cannulation of TVs can be tested and stent struts bended if necessary, using balloon angioplasty. In our series 65% of cases were managed with a fenestrated or branched cuff only, resulting in an adequate seal between the cuff and the pre-existing infrarenal graft. In many cases however, a complete relining of the original repair with a complementary bifurcated aorto-iliac system is required to obtain sufficient distal sealing. Pre-existing grafts with a short main body may cause problems with delivery of bifurcated extensions, which can be overcome with an inverted contralateral limb. Accurate orientation and delivery of endovascular stent grafts relies heavily on radio-opaque markers, the multitude of which can impede visualization of fenestrations as old and new grafts intersect in the field of vision. A preloaded fenestrated graft can be valuable in this regard, as the system comes with preloaded guidewires through the renal fenestrations. Introducers to the renal arteries are advanced over the wires and reach their target with relative ease facilitating cannulation of the TV effectively and safely. Secondary fenestrated and branched repair after previous infrarenal repair is a valid alternative to OSR, but detailed planning is essential to obtain good results.

For patients with jAAA in urgent need of repair, as is the case for rapidly growing AAA, symptomatic AAA or in the case of rupture, the time-consuming manufacturing and shipping of CMDs is a limiting factor. The COOK Zenith p-Branch device was developed to address this issue, readily available “off-the-shelf” in emergent settings, and anatomically applicable in up to 50-70% of jAAs. In paper III we found early outcomes comparable with CMDs, although re-intervention rates were somewhat inferior. Adequate proximal seal was achieved in all cases, indicating that the graft-configuration with fenestrations to the SMA and renal arteries and a scallop for the CT is sufficient to this end. Other studies have shown a gain in infra-coeliac seal compared to supra-coeliac regarding survival, spinal ischemia and over-all branch re-intervention rates. In our series long-term outcomes were in some aspects comparable with repair with CMDs, such as survival and diminishing aneurysm sac diameter. TV stability, renal function and re-intervention rates were however inferior to outcomes after CMDs. Outcomes for patients treated in emergent settings carry weight in these results, perhaps understandably since it is well known that urgent surgery often arises outside office hours and demands hurried planning and action in patients in poor clinical condition. Another likely explanation is the pivoted design of the renal fenestrations. Not only are they more challenging to cannulate compared to the more rigid fenestrations of CMDs as the targeted arteries are often offset by a larger margin, but they are additionally prone to fluctuate during cannulation as well as after deployment due to pulsating blood-flow. Overall, performance of the p-
Branch device is somewhat inferior to CMDs. It can be a suitable choice in urgent settings when patients are deemed unfit for OSR and infrarenal EVAR is not an option.

FEVAR has been shown to be a safe and efficient option for managing jAAA in the short- and mid-term\textsuperscript{154}. However, long-term data is lacking. A previous report showed promising 5-year outcomes after the first 54 patients treated with FEVAR in Vascular Center Malmo\textsuperscript{90}. In paper IV, a median FU of 89 months in 94 succeeding patients offers an extended insight regarding long-term outcomes and graft performance. TV patency was 94%, 90% and 89% after one, three and five years respectively which is similar to similar studies\textsuperscript{88,94}. Unstented SMA scallops were at greater risk of resulting in compromised patency, as other studies have shown\textsuperscript{155}. Branch EL occurred in only one (0.5%) TV, which compares favourably to earlier reports of rates up to 4-5\textsuperscript{156}. 65% of reinterventions were performed to address EL or TV instability, highlighting the impact of these adverse outcomes after fenestrated repair. Impact on renal function after FEVAR is a well-known issue. Per-operative guidewire- and catheter-related injuries in the renal arteries during cannulation as well as post-operative stent dysfunction are contributing factors, and studies have shown declining renal function in 25-29\% of cases\textsuperscript{95,96}. However, there is some evidence indicating no difference in renal impairment after FEVAR compared to EVAR\textsuperscript{157}. Studies have found a lower incidence of renal dysfunction after FEVAR compared to OSR\textsuperscript{75,158}, perhaps indicating that FEVAR should be favoured in the management of jAAA. Long-term FU in our series indicates favourable outcomes regarding renal function with 16% of patients with normal GFR pre-operatively developing insufficiency to some degree. Comparing long-term outcomes between the early-phase and the late-phase cohorts from paper I we saw a reduction in operative mortality (3.7\% vs 1\%), in 5-year mortality (40\% vs 29\%) and over-all aneurysm sac diameter (71\% vs 91\%), as well as increased 5-year re-intervention free survival (56\% vs 60\%) respectively. This may point to a benefit in increased experience and more extensive endovascular repair regarding long-term survival. A sizable portion of re-interventions were prompted by findings outside of regular FU, often instigated by patient symptoms. The majority of TV instability was detected early during FU. This may imply that the cause for instability arises early post-operatively or may already be present albeit undetected at the end of the initial procedure. Studies have shown that CBCT outperforms CTA and DSA in the detection of EL after FEVAR\textsuperscript{159}, and the technique is also more sensitive than DSA for detection of device kinking after EVAR\textsuperscript{160}. Re-intervention rates might have been reduced with the aid of a final CBCT intra-operatively, which by extension could in turn lessen the need for repeated CTA controls later during FU. As the application of CBCT was gradually introduced at Vascular Center during the study inclusion period and thus not applied in all cases, CBCT data was not analyzed in this study. Almost all cases of EL were accompanied by aneurysm sac enlargement. Sac diameter measurements and TV EL detection is quite feasible using DUS\textsuperscript{161,162}. It is possible that a combination of intra-operative CBCT and
extended application of DUS during FU may alleviate the need for post-operative CTA surveillance, in turn minimizing patient radiation exposure and nephrotoxicity.
Conclusions

1. With increasing experience FEVAR design has become more complex involving more TVs and moving the sealing-zone more proximally. This has not resulted in longer procedure durations or increased complications and operative risk remains low. Despite an increased number of fenestrations, radiation time and contrast-media load are reduced.

2. Despite technical difficulties and necessary meticulous planning, F/BEVAR for type 1a endoleaks, proximal aneurysm or pseudoaneurysm formation and device migration after previous infrarenal AAA repair is a safe and effective treatment method, and a reasonable alternative to OSR.

3. The COOK Zenith p-Branch device is a safe and effective means of managing jAAA both electively and emergently in selected patients, with acceptable long-term outcomes. Treatment with CMD is preferable in applicable circumstances.

4. Long-term outcomes after FEVAR for jAAA remain good with improved overall survival and AAA related mortality with increased experience despite a larger number of fenestrations. Survival and renal function compare favourably to OSR, although the need for reinterventions remains a challenge.
Abdominal aortic aneurysm repair has progressed decisively in the last decades after a period of stagnation when open surgical techniques reached their peak. With endovascular abdominal aortic repair a new era emerged bringing extended possibilities. As only about half of AAAs are suitable for infrarenal repair, a continuous development of fenestrated graft design is called for. Design and deployment of these devices is complex, and increased experience in pre-operative planning as well as intra-operative techniques is of the essence to assure the best possible outcome for each individual patient. Managing jAAA disease in urgent settings brings an additional spectrum of concerns, as the current waiting time for custom made grafts is not realistic in these cases. OTS devices have been developed to address this issue, but further innovation is warranted to overcome problems with device performance and durability. Particular focus needs to be aimed at fenestration stability while simultaneously preserving a degree of manoeuvrability to facilitate a secure TV perfusion.

The main concerns in managing jAAA with FEVAR revolve around proximal EL and TV instability, and early identification and proper handling of these issues is key to minimize the risk of adverse outcomes and patient harm. Intra-operative measures such as CBCT may reduce the risk of missed EL and graft kinking as studies have illustrated. Increased employment of this technique may further reduce the need for re-interventions and the risk of negative outcomes, and many centres have the application available. Recent work with DUS as a modality for FU after FEVAR has also shown promising outcomes in detecting EL and TV patency. By such preventive measures it can be argued that the need for rigorous post-operative follow-up using CTA could be diminished, thereby reducing patient radiation exposure, iodine-based contrast medium exposure and health care cost. More research is needed to address this issue.
Populärvetenskaplig sammanfattning

Bukaortaaneurysm är ett tillstånd när dilatation sker på stora kroppspulsådern i buken. Tillståndet föreligger hos upp till 1.5-2.6% av svenska befolkningen vid 65 års ålder och drabbar i synnerhet män. Orsaker till att detta äger rum är flera, men främst föreligger ett samband mellan aneurysmbildning och rökning, äftlighet, högt blodtryck, ålder och manligt kön. Ju större aneurysmet är desto mer ökar risken för att kärlbrott med ödesdigra konsekvenser för patienten. Då sker en omfattande invärtes blödning som i många fall leder till döden. Tidigare forskning har visat att risken för ruptur överstiger den risk som ett förebyggande kirurgiskt ingrepp medför när kärlvidningen når 5.5 cm diameter hos män och 5.0 cm hos kvinnor. Huvudsakligen används två olika behandlingsmetoder: Öppen kirurgi då den drabbade delen av aorta byts ut mot en insydd tub av tyg via ett stort snitt på buken, alternativt en minimal-invasiv endovaskulär metod (EVAR) då en metallförstärkt protes av tyg införskaffas i genomlyftning via punktionshål i ljudspulsådorna och fodrar kärlets vägg. Den sistnämnda metoden har de senaste åren utvecklats i rask takt för att även användas för komplexa bukaortaaneurysm som innefattar kärlvälvningar till viktiga bukorgan som lever, tarmar och njurar. Då kallas ingreppet FEVAR (fenestrerad EVAR). Protesen är då försedd med hål eller urgröpningar i tyget så att blod ska rinna ohindrat till de olika bukorganen. Protesserna har individuell design i varje enskilt fall beroende på aneurysmets anatomi.


Syftet med denna avhandling var att utvärdera utfallet av behandling med FEVAR av komplexa bukaortaaneurysm avseende patientsäkerhet och protessernas hållbarhet. Den består av fyra olika delarbeten (I-IV).
Studiernas specifika syfte var att:

I. Utvärdera hur erfarenhet av FEVAR påverkar protesernas design, operationsförörande och kliniskt utfall.

II. Utvärdera användbarhet av FEVAR som kompletterande åtgärd efter tidigare ingrepp på bukaorta.

III. Utvärdera hållbarhet och kliniskt utfall av FEVAR med en standardiserad protes i planerade och akuta fäll.

IV. Utvärdera långtidsresultat efter FEVAR.


Med ökad erfarenhet minskade genomlysningstid och kontrastmängd, och tendens ökade till antal fenestreringar i protesdesign. Överlevnad efter FEVAR förbättras även med ökad erfarenhet. Kompletterande behandling med FEVAR efter tidigare ingrepp på bukaorta med otillräcklig effekt är en säker och hållbar behandlingsmetod, men tekniska utmaningar kallar på noggrann bildoagnostisk planering. Behandling med standardiserad protes av komplexa bukaortaaneurysmer tillfredsställande resultat för utvalda patienter, i synnerhet under brådskande förhållanden. FEVAR är en säker och hållbar behandling på lång sikt, och bör favoriseras över öppen kirurgi om adekvat kompetens och lokala resurser föreligger.

Slutsatserna av denna avhandling är att FEVAR är en säker behandlingsmetod för komplexa bukaortaaneurysmer. Förbättrad överlevnad och sjunkande komplikationsfrekvens motiverar att FEVAR framhålls som första behandlingsalternativ. Metoden är relativt ny, och fortsatt forskning kring stentgrafters hållbarhet på lång sikt är befogad.
Samantekt á Íslensku

Ósæðargúll í kviðarholi myndast er víkkun á ósæðinni á sér stað. Algengi ósæðargúls í kviðarholi er 1.5-2.6% við 65 ára aldur hjá sænsku þjóðinni og er algengara í karlmönnum. Myndun ósæðargúls á sér margar ástæður, áhættuþættir eru einkum reykingar, hár blöðþrýstingur, hækkandi aldur, erfðir og karlkynd. Æðagúlar geta stækkað með tímanum, og með aukinni æðavíkkun eykst hættu á rofi með alvarlegum afleiðingum. Þá verður umfangsmikil innvortis blæðing sem í flestum tilvikum leiðir til dauða sjúklinguins. Rannsóknir hafta synt að hættu á rofi er meiri en áhættu við fyrirbyggjandi aðgerð ef þvermál ósæðagúls nær 5.5 cm hjá karlmönnum og 5.0 cm hjá konum, og við þau mörk er sjúklingum almennt ráðlögo aðgerð. Tvær mismunandi aðgerðir standa sjúklingum til bøða: opin aðgerð þegar framanverður kviðveggur er skorinn upp og sjúka hluta ósæðarinnar er skipt út fyrir gerviæð sem saumðu er fóst, eða innæðaadur aðgerð (EVAR) þegar málmystrktri gerviæð er komið fyrir í gúlnum innanverðum gegnum stungur á náraslagaeðum með hjálp gegnumþysingar með röngtækn. EVAR hefur þróast hrasti síðustu ár, ekki síst hvað varðar flöknari gerðir ósæðargúla sem myndast við øðagreinar er veita blöði til mikilvægra kviðarholslíffera, svo sem lífrar, þarma og nyrna. Sú tegund innæðaadur er nefnd FEVAR (fenestrated EVAR). Gerviæðin sem þá er notuð er framleidd með götum eða úrtekt úr efni gerviæðarinnar sem veita Óhindrað blöðflæði til lífferaanna. Í þessum tilfellum er gerviæðin sérstaklega hönnuð og framleidd fyrir hvern einstakling þar sem ósæð hvers og eins er einstök í útiliti og formgerð.

Tilgangur þessarar ritgerðar var að meta árangur aðgerða með FEVAR vegna flókinna ósæðargúla í kviðårholi með tilliti til óryggis sjúklinga og haldbænri grevíaða. Hún samanstendur af fjórum rannsóknurnum (I-IV)

Tilgangur rannsóknannar var að:

I. Meta áhrif reynslu í framkvæmd FEVAR á hönnun gervíaða, aðgerðaraðferðir og klinískar niðurstöður.

II. Meta notagildi FEVAR sem úrræði við ófullnægjandi áhrifum af fyrri aðgerðum vegna ósæðargúls í kvið.

III. Meta haldbænri og klinískar niðurstöður eftir FEVAR með staðlaðri gervíað í valkvæðum aðgerðum og bráðaadgerðum.

IV. Meta langtímaárangur eftir aðgerð með FEVAR.


Með aukinni reynslu minnkaði tími gegnumlýsingar og notkun skuggaefnis í aðgerðum þrátt fyrir flóknari hönnun gervíaða. Lifun eftir aðgerð jókst milli hópa með aukinni reynslu. Viðbótaraðgerð með FEVAR eftir fyrri aðgerðir á ósæðargúl í kviðårholi er örugg og haldbær, en tæknilegar áskoranir krefjað þekvemrar forvinnu við myndgreiningu og kortlagningu gúls. Góðar niðurstöður fást eftir FEVAR með staðlaðri gervíað hjá völdum höpi sjúklinga, einum eftir bráðaadgerð. FEVAR er örugg og haldbær aðgerð til langs tíma, og er tilvalið fyrsta úrræði við meðhöndlun flókinna ósæðargúla í kvið ef reynsla og staðbundnar aðstæður leyfa.

Niðurstöður ritgerðar þessarar sýna því að FEVAR er örugg meðhöndlun við flóknum ósæðargúl í kviðårholi. Bætt lifun og fækkan fylgikvilla ýttir undir FEVAR sem fyrsta aðgerðarval. Áðferðin er tiltölulega ný, og fleiri rannsóknur er varða langtíma haldbænri er þörf.
Acknowledgements

I would like to express my utmost gratitude to the following people:

Professor **Timothy Resch**, my principal supervisor, mentor and friend. Thank you for everything! Your tireless advice and commitment have been invaluable through the process from start to finish. Thank you for all your support, in good times and bad. You are truly my bottomless source of inspiration.

Associate professor **Þórarinn Kristmundsson**, my co-supervisor and friend. Your spotless work ethics have guided me more than you know, and I am forever grateful for your direction and support.

My co-authors **Björn Sonesson**, **Nuno Dias** and **Katarina Björses** for their valuable input and guidance.

My colleagues in the Vascular unit in Helsingborg, **Johan Magnusson**, **Hans Lindgren**, **Tobias Kühme**, **Magnus Garbergs**, **Gustav Torstensson** and **Christian von Heijne** for cheering me on and for making room in in our schedule for my research.

All my colleagues at the Department of Surgery in Helsingborg and in Vascular Center Malmö for your friendship and support.

**Kjerstín Ädel Malmborg** and **Margareta Warvsten**, the masters of misplaced folders.

My parents **Kristín Bragadóttir** and **Sveinn Magnússon**, and my siblings **Sigríður Sveinsdóttir**, **Bragi Sveinsson** and **Kristín Björg Sveinsdóttir**. Thank you all for believing in me.

My beloved wife and soulmate **Þóra Briem**, and my children **Tinna** and **Sveinn**. I think we all deserve a big hug-fest!
References

4. Antoniou GA, Antoniou AI, Antoniou SA, Lazarides MK. A historical perspective of
6. Blakemore AH. Progressive constrictive occlusion of the abdominal aorta with
wiring and electrothermic coagulation, a one-stage operation for arteriosclerotic
7. Moore CH, Murchison C. On a new method of procuring the consolidation of Fibrin
in certain incurable Aneurisms: With the Report of a case in which an Aneurism of
the ascending Aorta was treated by the insertion of Wire. Med Chir Trans.
1864;47:129-49.
9. Poppe JK. Cellophane treatment of syphilitic aneurysms with report of results in six
10. Matas R. I. An Operation for the Radical Cure of Aneurism based upon
11. Matas R. Some Experiences and Observations in the Treatment of Arteriovenous
Aneurisms by the Intrasaccular Method of Suture (Endo-Aneurismorrhaphy) with
12. Dubost C, Allary M, Oeconomos N. Resection of an aneurysm of the abdominal
aorta: reestablishment of the continuity by a preserved human arterial graft, with
result after five months. AMA Arch Surg. 1952;64(3):405-8.
13. Julian OC, Grove WJ, Dye WS, Olwin J, Sadove MS. Direct surgery of
arteriosclerosis; resection of abdominal aorta with homologous aortic graft


juxtarenal abdominal aortic aneurysms over the last 10 years. BJS Open. 2019;3(5):572-84.


Appendix

Study inclusion- and exclusion criteria for paper III, provided by Cook Research Incorporated.

Inclusion Criteria

Pararenal or juxtarenal AAA ≥ 5.0 cm in diameter

Pararenal or juxtarenal AAA with history of growth ≥ 5.0 cm / year

Exclusion Criteria

General

Age < 18 years

Life expectancy < 2 years

Pregnant or breast feeding

Inability or refusal to give informed consent

Unwilling or unable to comply with follow-up schedule

Medical

Cultural objection to receipt of blood or blood products

Allergy to stainless steel, polyester, solder, gold or nitinol

Anaphylactic reaction to contrast that cannot be adequately pre-medicated

Uncorrectable coagulopathy

Previous orificial stent in any vessel to be accommodated with the SMA fenestration or pivot fenestrations that protrudes into the aorta
Anatomical

Proximal sealing zone length < 15 mm (between the distal-most aspect of the celiac artery and the proximal end of the aneurysmal aorta)

Greater than 10% increase in diameter over the length of the proximal sealing zone

Proximal sealing zone angulated > 60 degrees relative to the centerline of the aneurysm and > 45 degrees relative to the suprareciac aorta

Aortic neck diameter > 31 mm or < 21 mm (outer diameter)

Renal and visceral vessel anatomy incompatible with graft

Non-bifurcated segment of any artery to be stented < 15 mm in length if use of covered stents is planned

Renal artery or SMA stenosis > 80%

Inability to maintain at least one patent hypogastric artery

Prohibitive occlusive disease, tortuosity, calcification, or thrombus of the proximal sealing zone

Tortuosity, calcification, or arterial diameter not conductive to placement of the introducer with use of a conduit